Comparing new treatment for relapsed B-ALL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a new injectable drug called BLB101 compared to a standard treatment (Blincyto) for adults with a type of leukemia called B-ALL that has come back or not responded to treatment. It may help you if your leukemia has the CD19 protein and you have had 1 to 2 previous treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- Your leukemia is called B-ALL and tests positive for the CD19 protein (your doctor can check this)
- Your leukemia is 'Philadelphia chromosome negative' (a specific genetic test result)
- You have had 1 to 2 previous treatments, and your leukemia either did not respond or came back after treatment
- You are able to care for yourself (ECOG score of 0 to 2) and weigh at least 45 kg (about 100 pounds)
- Your liver, kidney, and heart function are within acceptable limits for this study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a targeted drug (blinatumomab) with a lower dose of standard chemotherapy for adults newly diagnosed with a certain type of B-cell acute lymphoblastic leukemia. The goal is to see if this approach is effective and causes fewer side effects than full-dose chemotherapy.
This study tests a new treatment for adults newly diagnosed with a type of leukemia called B-ALL. It uses a lower dose of chemotherapy followed by a 14-day course of blinatumomab, which helps the immune system fight cancer cells. This approach may reduce side effects while still being effective.
This trial tests if a new drug, RDC-Blinatumomab, works better than the usual chemotherapy (hyperCVAD) for people with a type of leukemia called Ph-negative B-ALL. It is for newly diagnosed patients who haven't had other treatments yet.
This study tests a drug called blinatumomab for people whose leukemia returns in a very early, hidden way after a stem cell transplant. The goal is to see if this drug can clear those leftover leukemia cells and help keep the disease from coming back.
This trial tests whether a drug called blinatumomab can clear leftover leukemia cells in children with B-cell acute lymphoblastic leukemia (B-ALL) who still have traces of disease after standard treatment. It aims to reduce the chance of relapse.
This study compares two ways of giving blinatumomab (a drug that helps your immune system find and kill leukaemia cells): as a continuous intravenous (IV) infusion versus a simpler subcutaneous (under the skin) injection. It is for adults newly diagnosed with B-cell precursor ALL, and the goal is to see if the subcutaneous injection works just as well while being more convenient.
Hear when a new Precursor B-cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.